



Short version of press release from Emotra AB
Gothenburg August 28, 2013

Agreement with Institute II for Psychiatry and Neurology in Warsaw

- *In clinical studies a strong relationship between hyporeactivity and risk for suicide has been demonstrated*
- *Emotra has developed, EDOR, ElektroDermal Orientation Reactivity, and objective and quantitative psychophysiological test for the measurement of hyporeactivity*
- *Evaluation of suicide risk is the most challenging problem for the psychiatric care to solve*

Emotra has signed an agreement with Institute II for Psychiatry and Neurology in Warsaw, about clinical evaluation of EDOR, for test of hyporeactivity. The Institute II for Psychiatry and Neurology is the first of about 15 leading clinical centers in Europe, which will evaluate routine use of Emotra's unique test method.

Emotra has ongoing discussion with a number of other clinical teams about the conditions for cooperation. Emotra will press release new contracts and continuously report on the ongoing studies. According to the time schedule should most of the clinical teams have completed the tests and patient follow up before the end of 2015.

When the support for EDOR from these clinical teams, is strong enough, the method will be launched in Europe. This can certainly happen before all clinics have completed their studies. CE-marking of the product will be finalized during the next six months. All work in Emotra will be performed in a small organization and at a low cost level.

The psychiatric care has relevant preventive actions and resources to use when risk for suicide has been identified. Unfortunately there are today no accurate methods for the identification of risk patients, with the use of EDOR this difficult diagnostic problem can be solved. The test does not take more than 15 minutes. With necessary preparations, the total time is 30 minutes. The introduction of EDOR as a clinical routine procedure has the potential to substantially reduce the number of suicides and suicide attempts in the world.

For more information, please contact

Claes Holmberg, President and CEO, Emotra AB, Telephone: +46708254547, claes@emotra.se

or Lars-Håkan Thorell, Research Manager, Emotra AB, Telephone: +46703263853, lars@emotra.se

Emotra AB is a Swedish medical device company focusing on research, development, clinical trials and marketing within the field of suicide prevention. The company's method, EDOR, is an objective and quantitative diagnostic psychophysiological test of hyporeactivity. During the test, the patients listen and react to a series of sound signals. The response is measured as minimal fluctuations in the dermal electrical conductivity and analyzed. With research and clinical documentation an extremely sensitive and accurate test, with the purpose of evaluating suicide risk, has been developed.

Emotra AB, Göteborgsvägen 74, 433 63 Sävedalen, Sweden

Telephone: +46 708 25 45 47, www.emotra.se